University of Texas System

Takeda Pharmaceutical Company Limited

Katy Rezvani

Elizabeth J Shpall

Raghu Kalluri

Lucila Nassif Kerbauy

Sushrut Kamerkar

Valerie Lebleu

Mayela Mendt

Michael David Curley

LeeAnn Talarico

Muharrem Muftuoglu

Rafet Basar

Prashanth Vishwanath

James Wilson Meador, Iii

Enli Liu

Paul Lin

Sonny OT Ang

Provided herein are methods for pre-activating and expanding an isolated population of NK cells. Further provided herein are methods for the treatment of cancer by administering the pre-activated and expanded NK cells.

Methods for activation and expansion of natural killer cells and uses thereof

Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosome.

Methods for production of MSC-derived exosomes

The present application provides BCMA targeting chimeric antigen receptor (CAR) comprising a BCMA binding region and an intracellular costimulatory domain derived from DAP10. Further provided are engineered immune effector cells (such as NK cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

BCMA chimeric antigen receptors and uses thereof

Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosomes.

Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells.

Immune cells expressing engineered antigen receptors

The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.

Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

Growing community of inventors

Houston, TX, United States of America

Katy Rezvani